New combo shows promise for Hard-to-Treat GI cancers
NCT ID NCT05205330
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests a combination of two drugs—vorbipiprant and balstilimab—in people with advanced colorectal or other gastrointestinal cancers that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 107 participants will receive the treatment, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, 56126, Italy
-
Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, Padova, 35128, Italy
Conditions
Explore the condition pages connected to this study.